- Diagnostic Différentiel
- Maladies
- Médicaments
- Plus
-
- Essayez d'établir votre recherche sur un attribut à la fois, et soyez aussi spécifique que possible! Exemple : "toux chronique".
- Ne pas entrer les résultats multiples tels que "anémie, toux chronique, perte de poids, vomissant" tous en même temps.
- Après sélection de votre attribut, une liste de diagnostics possibles sera générée. Si la liste est trop longue, vous pourrez la réduire en écrivant des attribut additionnels.
- Ne pas écrire les valeurs telles que le "rythme cardiaque 110" ou le "sodium 125", mais plutôt "tachycardie" ou "hyponatrémie".
Drug Information for Fluoxetine Hydrochloride (Northstar Rx LLC): CONTRAINDICATIONS
- BOXED WARNING
- DESCRIPTION
- CLINICAL TRIALS
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- DRUG ABUSE AND DEPENDENCE
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- ANIMAL PHARMACOLOGY/TOXICOLOGY
- Medication Guide
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 10 mg (1000 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg (1000 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (30 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (100 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (500 count)
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg (1000 count)
- Liens externes liés à Fluoxetine Hydrochloride (Northstar Rx LLC)
- Fluoxetine is contraindicated in patients known to be hypersensitive to it. Monoamine oxidase inhibitors - There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, fluoxetine should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Since fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks [perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses (see Accumulation and slow elimination under CLINICAL PHARMACOLOGY)] should be allowed after stopping fluoxetine capsules before starting an MAOI. Pimozide - Concomitant use in patients taking pimozide is contraindicated (see PRECAUTIONS). Thioridazine - Thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued (see WARNINGS).
- Drug Information Provided by National Library of Medicine (NLM).
Ce site est destiné à être utilisé principalement comme un système de rappel pour les médecins qualifiés et d'autres professionnels médicaux. En utilisant ce site vous comprenez et acceptez que DiagnosisPro.com ne doit pas être employé comme un système de (Conditions d'utilisation). Ce site respecte les principes de la charte HONcode. Vérifiez ici.
© 2013 MedTech USA, Inc. (modifié le 06/19/13)
